Rituxan Market Expansion In Rheumatoid Arthritis Patients Sidelined By PML Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issues a "complete response" to Genentech/Biogen Idec for sBLA for Rituxan in earlier-stage rheumatoid arthritis.